<DOC>
	<DOCNO>NCT01149915</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose , dose limit toxicity , safety tolerability TH-302 patient acute leukemia , advance phase chronic myelogenous leukemia ( CML ) , high risk myelodysplastic syndrome , advance myelofibrosis relapsed/refractory chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Study Hypoxia-Activated Prodrug TH-302 Treat Advanced Leukemias</brief_title>
	<detailed_description>Tumor hypoxia associate resistance chemotherapy radiotherapy ( Brown et al , 2004 ; Boyle 2006 ) . TH-302 , hypoxia activate prodrug ( HAP ) , exploit hypoxic nature tumor little effect normal tissue . TH-302 belongs class alkylating agent call oxazaphosphorines major experimental clinical activity ( Brock 1989 ) . Since TH-302 selectively target hypoxic microenvironment , agent may represent improvement agent class . Preclinical data support hypothesis TH-302 target hypoxic region tumor also able kill tumor cell normoxic region result cytotoxin diffusion , lead significant effect tumor growth . Preclinical data show TH-302 anti-tumor activity multiple myeloma cell vivo vitro . Additional preclinical data demonstrate marked expansion hypoxic bone marrow area diseased mice ALL . These result suggest agent may useful treat advanced leukemia . The drug stable plasma liver , appear risk drug-drug interaction , mild , reversible toxicity . In dose-escalation study , patient advance leukemias receive infusion TH-302 determine maximum tolerate dose .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>At least 18 year age . Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee . Relapsed/refractory leukemias standard therapy option anticipate result durable remission . Acute myelogenous leukemia ( AML ) WHO classification relapse refractory standard chemotherapy ; unsuitable standard chemotherapy unwilling undergo standard chemotherapy . Acute lymphoblastic leukemia ( ALL ) relapse refractory standard chemotherapy ; unsuitable standard chemotherapy unwilling undergo standard chemotherapy . Philadelphia chromosome ( Ph ) positive ALL eligible fail prior tyrosinekinase inhibitor therapy . Chronic myelogenous leukemia ( CML ) accelerate blast phase fail prior tyrosine kinasecontaining therapy Highrisk myelodysplastic syndrome ( MDS ) [ i.e . refractory anemia excess blast ( RAEB1 RAEB2 ) WHO classification ] chronic myelomonocytic leukemia ( CMML ) &gt; 5 % marrow blast , relapse refractory standard therapy Chronic lymphocytic leukemia ( CLL ) relapse refractory standard therapy , eligible protocol high priority Advanced myelofibrosis ( MF ) resistant refractory standard therapy ; untreated one follow feature ( 1 ) hemoglobin &lt; 10 g/dL , ( 2 ) platelet count &lt; 100 x 109/L , WBC &lt; 4 &gt; 30 x 109/L , splenomegaly ≥ 10 cm leave costal margin Age &gt; 60 year AML candidate refuse standard chemotherapy , exclude subject acute promyelocytic leukemia ( APL ) favorable cytogenetic abnormality [ inv16 , ( 8 ; 21 ) ] . ECOG performance status less equal 3 Adequate organ function indicate follow laboratory assessment perform within 14 day prior first dose study drug : Total bilirubin ≤ 1.5 time upper limit normal ( x ULN ) ( ≤ 3 x ULN due leukemic involvement Gilbert 's syndrome ) . Aspartate aminotransferase alanine aminotransferase ≤ 2.5 x ULN ( ≤ 5.0 x ULN due leukemic involvement ) Serum creatinine ≤ 1.5 x ULN . All woman childbearing potential must negative serum pregnancy test woman men subject must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) partner entry study 6 month last dose New York Heart Association ( NYHA ) Class III IV , cardiac disease , myocardial infarction within 6 month prior Day 1 , unstable arrhythmia Seizure disorder require anticonvulsant therapy Severe chronic obstructive pulmonary disease hypoxemia opinion investigator physiological state lead hypoxemia Major surgery , diagnostic surgery , within 4 week prior Day 1 , without complete recovery Active uncontrolled infection Systemic chemotherapy ( exception hydroxyurea and/or steroid ) within 14 day ( within 5 halflives investigational agent ) prior first dose study drug , unless evidence rapidly progressive disease . Concurrent therapy CNS prophylaxis continuation therapy control CNS disease permit . Known active infection HIV , hepatitis B , hepatitis C Patients exhibit allergic reaction similar structural compound , biological agent , formulation ( contain solutol and/or propylene glycol ) Females pregnant breastfeeding Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk subject study Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Advanced Leukemias</keyword>
	<keyword>Relapsed/Refractory Leukemias</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
	<keyword>MDS</keyword>
	<keyword>CLL</keyword>
	<keyword>MF</keyword>
	<keyword>Evofosfamide</keyword>
</DOC>